About the Authors

**Nureen Sumar, MD, MSc, CCFP**

Dr. Nureen Sumar is a Clinical Assistant Professor in the Department of Family Medicine at the University of Calgary and a General Practitioner Oncologist with Alberta Health Services. Dr. Sumar is an executive member of the Canadian Association of General Practitioners in Oncology and a member of the Cancer Care Member Interest Group at the College of Family Physicians of Canada. Dr. Sumar concurrently completed a Bachelor of Music (Jazz Theory and Voice) and a Bachelor of Science (Microbiology and Immunology) at McGill University prior to pursuing her Doctor of Medicine, Family Medicine residency, and fellowship in Primary Care Oncology at the University of Calgary. She went on to complete a Masters in Epidemiology at the London School of Hygiene and Tropical Medicine in the UK and Palliative Care Education and Practice training at Harvard Medical School’s Centre for Palliative Care. Her clinical scope includes GP oncology, palliative care and hospice medicine, addictions medicine, and medical education. After serving as the Medical Director of the newly launched AKUH@Home program and a Supportive and Palliative Care Consultant at the Aga Khan University Hospital in Nairobi, Kenya, Dr. Sumar returned home to Calgary where she is deepening her training and practice in Palliative Care.

**Affiliations:** Department of Family Medicine, University of Calgary, Calgary, Alberta, Department of Haematology-Oncology, Aga Khan University, Nairobi, Kenya

**Ali Poonja, MD**

Dr. Poonja is currently in his final year of residency training in Diagnostic Imaging at the University of Alberta. He earned his medical degree from the University of Alberta and his undergraduate degree in Health Sciences from the University of Calgary.

**Affiliations:** Department of Radiology, University of Alberta, Edmonton, Alberta
Conversations in Breast Cancer Screening: An Exploration of Age, Density, and Emerging Technologies

Nureen Sumar, MD, MSc, CCFP
Ali Poonja, MD

Introduction

Breast Cancer remains a significant burden in Canada, reflecting global patterns as one of the most common cancers affecting women. In 2023, it was estimated that 26% of all new cancer cases among Canadian women were attributed to breast cancer, contributing to 13% of all cancer deaths in this group. Recent advancements in both detection and treatment of breast cancer have significantly improved cure rates, particularly when breast cancer is detected early. Early-stage breast cancer detected through screening can have a 5-year survival rate of 99%. Thus, the quest for early detection through effective and economical screening initiatives is a critical component in minimizing the burden of disease and reducing breast cancer-related mortality.

However, ongoing dialogue continues within the medical community regarding the optimal timing of screening initiation for women at average risk. Discussion about the appropriate age to discontinue screening is an evolving topic. This conversation is complex and multifaceted, involving careful consideration of the intricate balance between the benefits of early detection, economic implications of population screening, and potential harms such as overdiagnosis and the psychological impact of false positives.

Current Canadian guidelines, last updated in 2018, recommended mammography screening every 2–3 years for women aged 50–74 years who are not at increased risk of breast cancer. These guidelines were independently reviewed using the AGREE II (Appraisal of Guidelines for Research and Evaluation) tool and were found to be of high quality. However, they are currently under review, with an anticipated release in 2024.

A recent review of breast cancer screening guidelines highlighted how the current Canadian...
recommendations differ from recently updated and comparable screening guidelines.\textsuperscript{10}

For example, in the United States, revised recommendations by the American Cancer Society (ACS) recommend that women at average risk should have the option to begin annual mammography at age 40 and should definitely begin by age 45.\textsuperscript{11} Early initiation of screening aims to reduce breast cancer mortality by diagnosing breast cancer in its earlier stages, which may be more favourable to treatment. The American College of Radiology (ACR) and the Society of Breast Imaging advocate for annual mammograms starting at age 40, citing significant reductions in mortality and increases in years of life saved.\textsuperscript{12} Recent Canadian studies also support early screening. One study concluded that starting mammography at age 40 can significantly decrease breast cancer mortality by enabling earlier diagnosis, where treatment may be more effective.\textsuperscript{13} Another study discusses the downstream impacts of organized screening programs in Canada, further advocating for the early initiation of screening.\textsuperscript{20}

**Arguments for Earlier Screening Initiation at Age 40**

Proponents of initiating breast cancer screening at the age of 40 emphasize the potential for early detection to reduce breast cancer mortality by up to 30%.\textsuperscript{14} A recent study, which involved hypothetical risk assessments and modelling, found that the age-based strategy detected more breast cancers but led to more false-positive mammograms and benign biopsy results. It went on to show that breast cancer in younger women tends to be more aggressive, highlighting the need for early detection.\textsuperscript{15}

Beyond mortality, early and localized detection of breast cancer can improve quality of life by allowing for breast conservation options versus mastectomies, thus potentially having more favourable psychosocial outcomes. Earlier stage cancers may also require less aggressive treatments, which may lead to fewer toxicities and late-effects. Canadian authors have conducted a comprehensive review of important non-mortality metrics and quality indicators that demonstrate alternative considerations in the debate on the age of population screening initiation.\textsuperscript{16}

**Arguments Against Earlier Age-Based Screening at Age 40**

Conversely, concerns about overdiagnosis, the benefits of early diagnosis given treatment advances, and the psychological impacts of false positives are ongoing. Overdiagnosis can lead to unnecessary treatments, which carry significant risks and side effects. Recent expert discussions suggest that a significant proportion of cancers detected through early screening may never become clinically significant.\textsuperscript{4} Furthermore, false positives may precipitate anxiety, stress, and invasive procedures.\textsuperscript{6}

Economic considerations may also play a role in this debate. Screening younger women for breast cancer more frequently can lead to increased healthcare costs, which may not be proportionate to the benefits in mortality reduction, especially with rapid advancements related to breast cancer diagnosis and treatment. For instance, the United Kingdom's National Health Service (NHS) continues to recommend routine screening at the age of 50, citing a more favourable balance of risks and benefits.\textsuperscript{10}

**Cessation of Breast Cancer Screening**

When to discontinue breast cancer screening is also being debated. Canadian guidelines recommend screening up to age 74, citing insufficient evidence to support screening beyond this age. However, they suggest the decision to continue beyond the age of 74 to be individualized and based on informed discussion, overall health, and patient preferences.\textsuperscript{5} The revised ACS guidelines recommend women continue mammography as long as they are in good health and expected to live beyond 10 years.\textsuperscript{11}

**Older Women: To Screen or Not to Screen?**

Proponents of screening cessation as women age cite diminishing returns, suggesting that competing causes of death reduces the relative impact of early detection of breast cancer. Some suggest that continuing mammography beyond the age of 70 does not significantly impact breast cancer mortality and may pose a greater risk of overdiagnosis. Additionally, screening may lead to the detection of slow growing tumours that would not have caused harm within their natural lifespan, possibly resulting in unnecessary treatments and associated morbidity.\textsuperscript{17-20}

Conversely, some experts argue that screening should continue for as long as women are in good health with a reasonable
life expectancy, as breast cancer risk increases with age.\textsuperscript{12,20,21} A recent study by Lee \textit{et al.} (2023) reports that screening mammography has favourable performance metrics in older women, with benefits outweighing the risk until age 90. Improved sensitivity and specificity lead to fewer false positives. They have also reviewed observational studies that demonstrate screen-detected cancers in older women are found at an earlier cancer stage, making them amenable to less invasive treatments. This highlights the importance of adaptable guidelines and individualized care.\textsuperscript{22}

Table 1 provides an overview of access to breast cancer screening across all Canadian provinces and territories, focusing on women aged 40–49 at average risk. Additionally, the table highlights the policies regarding breast density notification.

<table>
<thead>
<tr>
<th>Jurisdiction</th>
<th>Access to Screening</th>
<th>Breast Density Notification</th>
</tr>
</thead>
<tbody>
<tr>
<td>British Columbia</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Alberta</td>
<td>Yes with conditions*</td>
<td>Yes</td>
</tr>
<tr>
<td>Saskatchewan</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Manitoba</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Ontario</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Quebec</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>New Brunswick</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Nova Scotia</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Prince Edward Island</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Newfoundland and Labrador</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Yukon</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Northwest Territories</td>
<td>Yes with conditions*</td>
<td>Yes</td>
</tr>
<tr>
<td>Nunavut</td>
<td>No</td>
<td>No</td>
</tr>
</tbody>
</table>

*women can self-refer after the first referral is made by the family physician

\textbf{Table 1:} Jurisdictional Screening Access and Breast Density Reporting (Canada); provides an overview of access to breast cancer screening across all Canadian provinces and territories, focusing on women aged 40–49 at average-risk. Some provinces and territories allow for self-referral for mammogram, either directly or after an initial referral by family physician. Additionally, the table highlights the policies regarding breast density notification, including which provinces inform all women of their breast density and which inform only those with BI-RADS (Breast Imaging & Reporting Data System) D density.\textsuperscript{6} Adapted from Yong-Hing CJ \textit{et. al}, 2023.
Breast Density and Implications for Mammography

Understanding Breast Density

Breast density refers to the proportion of fibroglandular to fatty tissue in the breast visible on a mammogram. The BI-RADS (Breast Imaging Reporting and Data System) scoring system categorizes breast density into four levels:
- A (almost entirely fatty)
- B (scattered fibroglandular densities)
- C (heterogeneously dense), and
- D (extremely dense)

Women with a BI-RADS score of C or D are considered to have dense breasts.23,24

Implications

Dense breasts contain a higher percentage of fibroglandular tissue, which appears white on a mammogram, similar to the appearance of potential tumours, which complicates detection.7,25 Dense breast tissue not only complicates mammogram readings by obscuring tumours, thereby reducing the sensitivity of mammograms (resulting in lower detection rates), but also independently increases the risk of breast cancer.23,25,26 These challenges raise the urgency around the need for enhanced screening strategies for women with dense breasts who receive negative mammogram results.

Supplementary imaging for average-risk women with a BI-RADS score of C or D with negative mammography results

To address these challenges, supplementary screening modalities such as ultrasound and magnetic resonance imaging (MRI) are recommended. Canadian guidelines recommend the use of supplemental ultrasound for women with dense breasts following a negative mammogram result. MRI, however, is advised for women with extremely dense breasts or additional risk factors.7 The DENSE trial in Europe demonstrated that supplemental MRI significantly improved cancer detection rates in women with extremely dense breasts.5 By comparison, in the USA, the ACR suggests either supplemental MRI or ultrasound for women with dense breasts to improve detection rates.12

Current guidelines have adopted recommendations that emphasize a personalized risk assessment to determine the most appropriate screening strategy, balancing the benefits of early detection with the potential harms of overdiagnosis and false positives.

Advanced and Emerging Technologies

Evaluation of advanced imaging techniques such as handheld ultrasound versus automated whole breast ultrasound (AWBUS), digital breast tomosynthesis, and contrast-enhanced mammography are also being explored for their efficacy in improving cancer detection rates.27 Some provinces have already adopted these advanced technologies. Also emerging in breast cancer screening is the supplementary use of artificial intelligence (AI). AI algorithms may come to play an important role in triaging mammograms, streamlining radiologist workloads, in addition to improving cancer detection rates and diagnostic accuracy.28

Thermography

Thermography uses infrared technology to detect heat patterns and vascular flow in breast tissue and has sparked controversial dialogue with respect to its utilization in breast cancer screening. While it offers a non-invasive and radiation-free alternative to mammography, its efficacy has not been established. Studies show variable sensitivity and specificity in the diagnostic accuracy of thermography; however, recent advancements in AI may improve its accuracy. Current evidence strongly suggests that thermography should not replace conventional imaging modalities. However, it may have a utility in underserved areas where access to mammography is limited.29-31

Conclusions and Future Directions

Breast cancer remains one of the leading cancers affecting women with a significant population burden. The discourse on breast cancer screening in Canada remains an evolving and rich conversation, centred around when to initiate and cease breast cancer screening, while evaluating benefits, potential harms, risk factors, special populations, rapid advancements in imaging modalities, and cancer therapies. Current Canadian guidelines are under review by the Canadian Task Force for Preventive Health, with an anticipated release of the updated guidelines in 2024. As we await these updates, our focus remains on an evidence-based, individualized, and patient-centric approach that incorporates the importance of early detection in mitigating...
breast cancer related morbidity and mortality outcomes, while also mitigating the risks inherent in population screening initiatives.

Correspondence

Nureen Sumar, MD, MSc, CCFP
Email: nureen.sumar@albertahealthservices.ca

Financial Disclosures:

N.S.: None declared.
A.P.: None declared.

References


